Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 1/1997

01-12-1997 | ORIGINAL ARTICLE

Randomized, double-blind comparison of granisetron versus granisetron plus prednisolone as antiemetic prophylaxis during multiple-day cisplatin-based chemotherapy

Authors: J. Handberg, V. Wessel, L. Larsen, J. Herrstedt, H. H. Hansen

Published in: Supportive Care in Cancer | Issue 1/1997

Login to get access
Metadata
Title
Randomized, double-blind comparison of granisetron versus granisetron plus prednisolone as antiemetic prophylaxis during multiple-day cisplatin-based chemotherapy
Authors
J. Handberg
V. Wessel
L. Larsen
J. Herrstedt
H. H. Hansen
Publication date
01-12-1997
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 1/1997
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s005200050134

Other articles of this Issue 1/1997

Supportive Care in Cancer 1/1997 Go to the issue

SHORT COMMUNICATION

Lung fibrosis induced by paclitaxel

SPECIAL ARTICLE

Antiemetic research: a look to the future

REVIEW ARTICLE

Current concepts and challenges in the prevention and treatment of viral infections in immunocompromised cancer patients

Meeting Highlights

5th Congress of the European Association of Palliative Care

REVIEW ARTICLE

Progress in fighting systemic fungal infections in haematological neoplasia

ORIGINAL ARTICLE

Ambulatory management of varicella-zoster virus infection in immunocompromised cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits